Company intelligence / Profile preview

Summers Laboratories

Collegeville, Pennsylvania, United Statessumlab.com ↗

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

Summers Laboratories markets a portfolio of over a dozen FDA-regulated dermatological products for the treatment of common and niche skin conditions. Their product line includes both prescription and OTC topical agents for psoriasis, eczema/atopic dermatitis, acne, dandruff/seborrheic dermatitis, hyperkeratosis disorders, brittle nails/nail repair as well as diaper rash and fungal infections. Products are frequently recommended by dermatologists.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small moleculeTopical emollientTopical antifungalProteinCombination products
Industry: Biotech

Drug pipeline

6 assets

Tarsum

5 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Summers Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Summers Laboratories.

Explore the full profile